Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:35:11 EDT Mon 14 Oct 2024
Enter Symbol
or Name
USA
CA



Q:BBIO - BRIDGEBIO PHARMA INC - https://bridgebio.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BBIO - Q0.225.52·26.261.525.78-0.12-0.51,743.144,61610,19925.69  26.46  25.68544.32  21.6817:04:31Oct 0315 min RT 2¢

Recent Trades - Last 10 of 10199
Time ETExPriceChangeVolume
17:04:31Q25.78-0.12136,648
16:38:23Q25.78-0.124,727
16:29:02Q25.51-0.3915
16:06:37Q25.51-0.391
16:01:53Q25.78-0.121
16:01:51Q25.78-0.1242
16:01:49Q25.78-0.12275
16:01:32Q25.78-0.121,556
16:01:25Q25.78-0.12479
16:01:24Q25.78-0.12533

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-10-03 07:30U:BBIONews ReleaseBridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions
2024-09-30 07:30U:BBIONews ReleaseBridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
2024-09-27 18:00U:BBIONews ReleaseBridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events
2024-09-17 07:30U:BBIONews ReleaseBridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA
2024-09-10 16:45U:BBIONews ReleaseBridgeBio Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program
2024-09-10 16:45U:BBIONews ReleaseBridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)
2024-09-06 07:30U:BBIONews ReleaseBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2024-08-30 10:50U:BBIONews ReleaseBridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension
2024-08-29 07:30U:BBIONews ReleaseBridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024
2024-08-28 07:30U:BBIONews ReleaseBridgeBio Pharma to Participate in September Investor Events
2024-08-26 07:30U:BBIONews ReleaseBridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial Intelligence
2024-08-19 07:30U:BBIONews ReleaseBridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia
2024-08-08 07:30U:BBIONews ReleaseBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2024-08-01 07:30U:BBIONews ReleaseBridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update
2024-07-23 07:30U:BBIONews ReleaseBridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer
2024-07-05 16:31U:BBIONews ReleaseBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2024-06-18 07:30U:BBIONews ReleaseBridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
2024-06-10 07:30U:BBIONews ReleaseBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2024-06-06 07:30U:BBIONews ReleaseBridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference
2024-06-04 07:30U:BBIONews ReleaseBridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia